Information Provided By:
Fly News Breaks for November 16, 2018
SGEN
Nov 16, 2018 | 08:18 EDT
Cowen analyst Boris Peaker said the risk/reward for Seattle Genetics ahead of the ASH meeting is favorable given the shares' recent selloff. The company announced that ECHELON-2 met its primary endpoint and demonstrated improvement in CR and OS for A+CHP over standard of care CHOP, noted Peaker, who maintained his Market Perform rating and $71 price target on Seattle Genetics shares.
News For SGEN From the Last 2 Days
There are no results for your query SGEN